^
    8d
    Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study. (PubMed, ESMO Open)
    The activity of tiragolumab-containing regimens appeared similar to that of atezolizumab plus chemotherapy in randomised phase III trials in early-stage and advanced TNBC. The safety profile of all three regimens was consistent with previous experience of similar regimens in other tumour types and with symptoms of the underlying disease.
    P1 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • tiragolumab (RG6058)
    9d
    Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Oct 2025
    Trial primary completion date • Tumor mutational burden
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    12d
    An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities. (PubMed, J Biol Chem)
    In addition, the shed ectodomain of TIGIT maintains binding to CD155 and the tested clinical anti-TIGIT antibody, tiragolumab. Given the significant anti-TIGIT failures, these unexpected findings reveal potential saturation vulnerabilities of macaque CD155 and preclinical TIGIT antibodies by soluble shedded TIGIT ectodomain, contrary to the intended mechanism of action on the lymphocyte membrane. These results caution against extrapolation and question the suitability of cynomolgus and rhesus macaques for preclinical safety and dose estimation of TIGIT-targeted therapies.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
    |
    tiragolumab (RG6058)
    21d
    Imbrave 152: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (clinicaltrials.gov)
    P3, N=687, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Sep 2026 --> May 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    21d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    1m
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    SKYSCRAPER-08: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma (clinicaltrials.gov)
    P3, N=461, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • tiragolumab (RG6058)
    2ms
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Georgetown University | Recruiting --> Active, not recruiting | N=42 --> 29
    Enrollment closed • Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=56 --> 7
    Enrollment closed • Enrollment change
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (RG6058)
    2ms
    TIGIT Expression and Its Implications in Non-Small-Cell Lung Cancer Progression and Therapy: A Systematic Review. (PubMed, Int J Mol Sci)
    Clinical trials, particularly with the monoclonal antibody tiragolumab combined with PD-1/PD-L1 inhibitors, show promising synergistic effects...While phase III data remain limited, biomarker-driven, well-designed trials are essential. If validated, TIGIT blockade could become a key addition to immuno-oncology treatment strategies for NSCLC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    tiragolumab (RG6058)